Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the best high short interest stocks with huge upside potential. Earlier in ...

Intravenous thrombolysis remains a standard treatment for acute ischemic stroke within 4.5 hours after onset. Vascular ...

Compass Pathways said Monday it achieved its primary endpoint in an early readout from the largest-ever study of psilocybin ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...